Blood Transfusion and Agglutination
Blood Transfusion
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
You might also read
Articles linked to this work by shared authors, journal, and citation graph.
Updated: Mar 2, 2026

Preparation and Pathogen Inactivation of Double Dose Buffy Coat Platelet Products using the INTERCEPT Blood System
Published on: December 7, 2012
Audrey Magron1, Jonathan Laugier1, Patrick Provost1
1a Centre de Recherche du Centre Hospitalier Universitaire de Québec , Faculté de Médecine de l'Université Laval, Département de Microbiologie et Immunologie , Québec , QC , Canada.
Pathogen reduction technologies (PRTs) inactivate microbes in platelet concentrates, but their impact on platelet quality and transfusion safety requires further investigation. This review examines PRT advantages and disadvantages in transfusion medicine.
Area of Science:
Background:
Purpose of the Study:
Main Methods:
Main Results:
Conclusions: